MoonLake Immunotherapeutics
MLTX•NASDAQ•Healthcare•Biotechnology

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJorge da Silva
Founded2021
Employees100
CountrySwitzerland
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
Share ClassClass A Shares

Contact Information

Websitewww.moonlaketx.com
Phone41 415108022
Address
Dorfstrasse 29 Zug, 6300 Switzerland

Corporate Identifiers

CIK0001821586
CUSIP61559X104
ISINKY61559X1045
SIC2834

Leadership Team & Key Executives

Dr. Jorge Santos da Silva Ph.D.
Co-Founder, Chief Executive Officer and Director
Dr. Kristian Reich M.D., Ph.D.
Co-Founder and Chief Scientific Officer
Matthias Bodenstedt
Chief Financial Officer
Oliver Daltrop Ph.D.
Chief Operations Officer
Carla Bretes
Director of Investor Relations and External Communications
Nicolas Mosimann Ph.D.
General Counsel
Joana Cortez
Senior Director Legal and Compliance
Tino Anthamatten
Vice President of Marketing, Market Access and Pricing
Luciana Marques
Director of Human Resources, People and Culture
Nuala Brennan
Chief Clinical Development Officer